advanced search

Welcome: Guest

log in

The Pharmaceutical Market: Indonesia

Publication Date January 2009
Publisher Espicom
Product Type Report
Pages 74
ISBN Number not applicable
Product Code ESP00234
Buy this product or for assistance call +44 20 7060 7474

Summary

In November 2008, the Health Ministry introduced rules requiring drug companies to have production facilities in the country, in order to get licences to sell their products in Indonesia. The rules will affect 13 international companies that sell their products in Indonesia but do not have manufacturing facilities.

The economy is predicted to slow in 2009, expanding at just 3.5% compared to an estimated 6.1% in 2008 largely due to a lower demand for Indonesian exports. The stock market and the Indonesian rupiah took a beating in 2008. The government under president Bambang Susilo Yudhoyono faces the challenge of steadying its currency from further devaluation.

Public sector funding for healthcare is low, estimated at around US$4.4 billion in 2008 and the country continues to rely on international aid. Despite the present administration placing more emphasis on healthcare and funding, the insufficient number of health professionals and bureaucratic problems are hampering development.

Protection of intellectual property rights is generally regarded as inadequate in Indonesia and counterfeiting is also a major problem. Although the government has started to crackdown on distributors of counterfeit drugs, intellectual property protection for pharmaceuticals remains weak. The country remained on the US government's Watch List in 2008.

The domestic pharmaceutical manufacturing industry is strong and the country has become an attractive base for many multinational producers to operate. This is largely down to a cheap labour force and generally inexpensive production costs.

Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Content

  • 1. Executive Summary
  • 2. Introduction
  • 3. Current market size
  • 5. Generic usage
  • 6. OTC market
  • 7. Market projections & outlook
  • 8. Imports
  • 9. Domestic manufacturing
  • 10. Multinational Manufacturing
  • 11. Exports
  • 12. Research & development
  • 13. Pharmaceutical regulations
  • 14. Pricing & reimbursement
  • 15. Intellectual property
  • 16. Distribution & retail
  • 17. Demographics
  • 18. Healthcare system
  • 19. Health expenditure
  • 20. Healthcare infrastructure
  • 21. Healthcare personnel
  • 22. Directory
  • 23. Methodology & sources
  • 97. Appendix: healthcare statistics
Delivery Details

PDF:Delivered by email usually within 4 to 8 UK business hours.

Industry Events

2nd International Conference on Drug Discovery and Therapy

01 Feb 10 to 04 Feb 10
Dubai, United Arab Emirates
view summary >>

Proteins Congress

29 Oct 09 to 30 Oct 09
Berlin, Germany
view summary >>

#